VALYSTR · Stock research
Listed on NasdaqGS. What the market is pricing into Halozyme Therapeutics, Inc. (HALO) in the Healthcare sector: implied growth, valuation scenarios, SEC-filed financials, and what has moved the stock.
Healthcare · Biotechnology · market value about $14.6B · P/E 38.4 · revenue $1.7B (as of 2026-11-04)
Opening the full page… All companies · Research guides · What a reverse DCF shows